Hemas launches reflex

Harshini PERERA

There has been an improving demand for Over The Counter (OTC) products in the pharmaceuticals industry. It is expected that OTC products will grow into a sizeable business in the near future.

Hemas Pharmaceuticals has improved their sales and will be introducing a range of OTC products in the future, Hemas Pharmaceuticals (Pvt) Ltd., Managing Director, Sanjeewa Samaranayake told Daily News Business. Hemas Pharmaceuticals has launched reflex, a drug for osteoarthritis as their latest product in the OTC product segment. The product reflex is a novel drug which comes from Fullife Healthcare (Pvt) Ltd., a research-based company in India that is committed to providing innovative healthcare solutions to meet the many unmet needs of people around the world. "It is a unique dietary supplement that has been clinically proven to help provide relief from osteoarthritis symptoms and pain within three weeks," Samaranayake said.

It is a nutriceutical which can be purchased over the counter without a doctor's prescription.

The fruit or hip of Rosa canina (Rosehip), a type of wild rose, is the key ingredient in reflex that is a totally a natural product.

Rosehip, the key ingredient in reflex, is sourced from Europe and unlike other medications it is proven to have no side effects owing to the fact that it is a 100 percent natural product which also qualifies it as vegetarian product.

Rosehip extract derived from Rosa canina has an anti-inflammatory and antioxidative ingredient cocktail provided by nature.

This results in large quantities of naturally occurring vitamin C, vitamin E and bioflavonoids that are known to help reduce oxidative stress and support the maintenance of tissue integrity and health. Fullife Healthcare (Pvt) Ltd., headquartered in Mumbai, India has a subsidiary in the USA and the company expects to set up subsidiaries in Europe, South East Asia and UAE in the future.

The company has an in house Research and Development unit and there are eight manufacturing facilities and five manufacturing facilities in the countries such as USA and Brazil.